What You Need To Know
Enrollment is now available for phase 1 clinical oncology trials. If any patients are identified, please reach out to phase1referrals@hmhn.org or contact Martin E. Gutierrez, M.D. at 201-615-7251 to have the team set up a consultation appointment for your patient.
NSCLC:
- Dose Escalation:
- BMS IM043 (JNK Inhibitor)-IO refractory NSCLC
- SGNEGFRd2 (EGFR)- CRC,NSCLC, HNSCC
- Dose Expansion Car-T/T-Cell Engager
- BMS CA052 (CCR8)
- CLN619 (Anti-MICA/MICB)- NSCLC, endometrial
- CTX471 (41BB) - NSCLC, SCLC and melanoma
- DS1062 (TROP)- NSCLC
Ovarian:
- Dose Expansion Car-T/T-Cell Engager
- BMS CA052 (CCR8)
- 2Seventy Bio (MUC16)
- CLN619 (Anti-MICA/MICB) - ovarian, primary
- NSCLC, endometrial - peritoneal, fallopian tube cancer
- o Xencor (CLDN6)- ovarian, fallopian, peritoneal cancer; endometrium adenocarcinoma; germ cell tumor; NSCLC; GEJ; HCC
Other:
- Dose Escalation:
- Amgen AMG305 (BiTE)- positive MSLN and CDH3
- BI1501 (CD47)- All Comers
- Incyte161734 - KRASG12D
- Incyte 33890 (Bispecific PD-1 & TGFBR2 Inhibitor)- CRC, panc
- MK0472 (SHP2)- slots offered to sites on rotation basis ; All Comers
- mRNA4359 - melanoma, NSCLC
- Nuvation - HER2 breast
- La Roche BP44382 (IgG1)- ES-SCLC, NEC
- SGNEGFRd2 (EGFR)- CRC, NSCLC, HNSCC
- ZL1218 (IgG1κ mAb for hCCR8 or combo w/ Anti-PD-1)- r/r to PD1/L1 or CPI naive 3L or less
- ZL1310 (ADC against DLL3) met/ES- SCLC w/ PD during or following platinum based chemo; no more than 3 prior Lines in r/r setting
- Dose Expansion Car-T/T-Cell Engager:
- BMS CA052 (CCR8)
- Xencor (CLDN6)-
- CLN619 (Anti-MICA/MICB) - ovarian, fallopian, endometrial peritoneal cancer;
- CTX471 (41BB) - SCLC and endometrium melanoma adenocarcinoma; germ
- DS7300 (B7-H3)- Squamous cell tumor; NSCLC; GEJ; esophageal by request HCC expansion
- RAPA - HNSCC,
- Immunocore (TCR recognizing anti-CD3)- HLA-A*02:01 + & Melanoma,SCLC/NET PRAME positive tumor
- Apollo (STEAP2) –
- MK1084 (KRASG12C)- All prostate Comers
- Athena (GPC3)- HCC
- Jannsen Paloma-02 –
- BI1480 (STING)
- Nimbus 1150 (HPK1) All
- LYL845 (TIL) - Comers melanoma
Slots:
Amgen AMG305 (BiTE)- positive MSLN and CDH3
BI1501 (CD47)- All Comers
BGB26808 (HPK1) - by request
BGBA3055 (CCR8)- no slot
BGB30813 (DGK) - 2B ; All Comers
BMS IM043 (JNK Inhibitor)- IO refractory NSCLC
BMS CA120 (Helios)- no slots ; All Comers
Incyte161734 - KRASG12D
Incyte 33890 (Bispecific PD-1 & TGFBR2 Inhibitor)- CRC, panc
MK0472 (SHP2)- slots offered to sites on rotation basis ; All Comers
mRNA4359 - melanoma, NSCLC
NC410-02 - HGSOC
Nuvation - HER2 breast
La Roche BP44382 (IgG1)- ES-SCLC, NEC
Sanofi TCD17620 (Anti PD1 + IL15)- no slot ; All Comers
SGNEGFRd2 (EGFR)- CRC, NSCLC, HNSCC
Tallac (TRAAC)- no slot
XTX301 (IL-12)- no slot ; All Comers
ZL1218 (IgG1κ mAb for hCCR8 or combo w/ Anti-PD-1)- r/r to PD1/L1 or CPI naive 3L or less ZL1310 (ADC against DLL3) met/ES- SCLC w/ PD during or following platinum based chemo; no more than 3 prior Lines in r/r setting
Expansion Slots:
BMS CA052 (CCR8)
CLN619 (Anti-MICA/MICB) - NSCLC, endometrial
CTX471 (41BB) - NSCLC, SCLC and melanoma
DS1062 (TROP)- NSCLC
DS7300 (B7-H3)- Squamous esophageal by request expansion
Immunocore (TCR recognizing anti-CD3)- HLA-A*02:01 + & PRAME positive tumor oMK1084 (KRASG12C)- All Comers
Jannsen Paloma-02 -
Nimbus 1150 (HPK1) All Comers
Cell Therapy Slots and T Cell Engagers:
2Seventy Bio (MUC16) - ovarian, primary peritoneal, fallopian tube cancer
Apollo (STEAP2) - prostate
Athena (GPC3)- HCC
BI1480 (STING)
LYL845 (TIL) - melanoma
RAPA - HNSCC, Melanoma,SCLC/NET
Xencor (CLDN6)- ovarian, fallopian, peritoneal cancer; endometrium adenocarcinoma; germ cell tumor; NSCLC; GEJ; HCC